Table 4: Intracellular ADM concentration in K562 and K562/ADM cells under different administration methods of ADM+TTD (`X±SD).
|
Group |
ADM (μg/mL) |
|
|
10 |
20 |
|
|
K562 |
1.23±0.06 |
1.57±0.02 |
|
K562/ADM |
0.21±0.04a |
0.29±0.05a |
|
K562/ADM+AT |
0.73±0.02ab |
1.17±0.03ab |
|
K562/ADM+A+T |
0.28±0.05ac |
0.39±0.03ac |
|
K562/ADM+T+A |
0.56±0.03abc |
0.83±0.05abc |
Note：Group: K562: K562 cells were treated with ADM for 2 h; K562/ADM: K562/ADM cells were treated with ADM for 2 h; K562/ADM+AT: ADM and TTD were simultaneously applied to K562/ADM cells for 48h; K562/ADM+A+T: K562/ADM cells, first added ADM for 48 h, then added TTD for 48 h; K562/ADM+T+A: K562/ADM cells, first added TTD for 48 h, then added ADM for 48 h. Compared with group K562，ap<0.05；Compared with group K562/ADM，bp<0.05；Compared with K562/ADM+AT group in the combination administration group，cp<0.05.